Literature DB >> 16298647

Role of chemokine signaling pathways in pancreatic islet rejection during allo- and xenotransplantation.

S Sigrist1, N Ebel, A Langlois, D Bosco, C Toso, C Kleiss, K Mandes, T Berney, M Pinget, A Belcourt, L Kessler.   

Abstract

During transplantation, pancreatic islets release chemokines promoting macrophage attraction, hampering engraftment of islets. The aim of this work was to examine the mechanism of macrophage-pancreatic islets interaction that mediates islet rejection during transplantation. Human macrophages exposed to supernates of human and porcine pancreatic islets for the allogeneic and xenogeneic models, respectively, were evaluated for chemotaxis and expression of chemokine receptors (CCR-5). To modulate migration and identify the signaling pathway of macrophages, we tested pertussis toxin (PTX) to block Gi protein, and staurosporin and wortmannin to inhibit the protein kinase, and phosphoinositol-3 kinase, respectively. The addition of these agents significantly reduced macrophage migration induced by human islet supernates from 3.2 +/- 0.5 to 1.5 +/- 0.2, 0.9 +/- 0.1, and 1 +/- 0.1, respectively (P < .001, n = 3). In a xenotransplantation model, the reduction was less decreased, from 4.1 +/- 0.4 to 2.7 +/- 0.3 (P < .01), to 2.5 +/- 0.3 (P < .01), or to 1 +/- 0.1 (P < .001). Western blot analysis of chemokine receptor expression showed increased CCR-5 expression with human pancreatic islet supernates. Moreover, decreased islet purity increased CCR-5 expression. Pharmacologic study showed that PTX induced an increase in CCR-5 expression in allogeneic transplantation, whereas only staurosporin induced an increased receptor expression in the xenogeneic model, suggesting that chemokines participate in islet rejection even though the chemokine signaling pathways differ between allo- and xenotransplantation. Understanding the molecular mechanisms of islet rejection may improve graft survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16298647     DOI: 10.1016/j.transproceed.2005.09.048

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  6 in total

1.  Early barriers to neonatal porcine islet engraftment in a dual transplant model.

Authors:  K P Samy; R P Davis; Q Gao; B M Martin; M Song; J Cano; A B Farris; A McDonald; E K Gall; C R Dove; F V Leopardi; T How; K D Williams; G R Devi; B H Collins; A D Kirk
Journal:  Am J Transplant       Date:  2017-12-28       Impact factor: 8.086

2.  Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic beta-cells to correct diabetes in allogeneic mice.

Authors:  T Kojaoghlanian; A Joseph; A Follenzi; J H Zheng; M Leiser; N Fleischer; M S Horwitz; T P DiLorenzo; H Goldstein
Journal:  Gene Ther       Date:  2008-12-25       Impact factor: 5.250

3.  Isolation and characterization of a novel strain of mesenchymal stem cells from mouse umbilical cord: potential application in cell-based therapy.

Authors:  Wen-Wen Li; Yau-Huei Wei; Hung Li; Dar-Ming Lai; Teng-Nan Lin
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

4.  Pro-inflammatory and pro-oxidant status of pancreatic islet in vitro is controlled by TLR-4 and HO-1 pathways.

Authors:  Kevin Vivot; Allan Langlois; William Bietiger; Stéphanie Dal; Elodie Seyfritz; Michel Pinget; Nathalie Jeandidier; Elisa Maillard; Jean-Pierre Gies; Séverine Sigrist
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

5.  Rapamycin Augments the NMDA-Mediated TNF Suppression of MRSA-Stimulated RAW264.7 Murine Macrophages.

Authors:  Thomas Spentzas; Rebekah K H Shappley; Fabio Savorgnan; Elizabeth Meals; B Keith English
Journal:  Int J Inflam       Date:  2012-10-10

6.  Improvement of islet graft function using liraglutide is correlated with its anti-inflammatory properties.

Authors:  A Langlois; S Dal; K Vivot; C Mura; E Seyfritz; W Bietiger; C Dollinger; C Peronet; E Maillard; M Pinget; N Jeandidier; S Sigrist
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.